Journal issues > Issue 3, September 2012 > Concomitant JAK2 V617F positive essential thrombocytemia and BCR-ABL1 positive chronic myeloid leukaemia masked by imatinib therapy for a gastrointestinal stromal tumour

Concomitant JAK2 V617F positive essential thrombocytemia and BCR-ABL1 positive chronic myeloid leukaemia masked by imatinib therapy for a gastrointestinal stromal tumour

By: E. Del Biondo MD, H. De Raeve MD, PhD, G. Huysmans MD, K. Hendrickx MD, E. Wouters MD, P. Vandenberghe MD, PhD, P. Meeus MD

Summary

The coincidence of a Janus Kinase 2 (JAK2) V617F positive myeloproliferative neoplasm (MPN) and a BCR-ABL1 positive chronic myeloid leukaemia (CML) is rare. We present a patient whose bone marrow and peripheral blood showed typical features of essential thrombocytemia (ET). However, the normalisation of the white blood cell (WBC) count after therapy with imatinib for a gastrointestinal stromal tumour (GIST) suggests that an underlying CML was masked, as witnessed by the very low levels of BCR-ABL1 at the haematological diagnosis. The question remains if this is a case of two separate myeloid malignancies or a secondary event (BCR-ABL1 fusion) in a primary JAK2 V617F + ET.

(BELG J HEMATOL 2012:3:105–107)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top